Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Mycosis fungoides, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Nothing has been shown to change the natural history of early-stage mycosis fungoides, so every treatment given in early disease is for symptoms, and over-treatment is the commonest harm.
The time from first rash to diagnosis is measured in years, and no test identifies early mycosis fungoides reliably on a single biopsy.
Itch is the symptom people with this disease rank as the worst and there is no randomised trial of any treatment for it in mycosis fungoides.
Allogeneic transplant is the only treatment that produces long remissions in advanced disease, and no trial defines who should have it or when.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Early-stage mycosis fungoides has a life expectancy close to that of the general population and no treatment has been shown to change it, so every intervention in early disease is for symptoms; over-treatment is the commonest harm in this disease.
Itch is the symptom patients rank worst and there is no randomised trial of any anti-itch treatment in mycosis fungoides.
Allogeneic transplant is the only treatment that produces long remissions in advanced cutaneous T-cell lymphoma, and there is no trial defining who should have it or when.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
WHO-HAEM5 kept the variants of mycosis fungoides as subtypes and distinguished early from advanced clinical patterns within the folliculotropic category, because their outcomes differ.
Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy
Mogamulizumab improved progression-free survival over vorinostat in previously treated mycosis fungoides and Sezary syndrome; approved in August 2018.
Topical treatment of mycosis fungoides-type CTCL (Ledaga)
Brentuximab vedotin produced far more objective responses lasting at least four months than methotrexate or bexarotene; approved in November 2017.